Jodid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jodid

Quick Facts: Jodid

Property Description
Active ingredient Potassium Iodide (KI)
Form Oral tablet
Pharmacological class Thyroid agent / Anti-goitre agent
Common use Prophylaxis against iodine deficiency
Origin Inorganic iodine compound

What Type of Medicine is Jodid?

Jodid is a systematic, monocomponent pharmaceutical preparation whose active ingredient is Potassium Iodide (KI). The compound is classified fundamentally as an Antithyroid Agent and Anti-goitre agent, which means its primary action is focused on supporting the health and function of the thyroid gland. As iodine is an indispensable essential micronutrient, Jodid provides a defined, measurable source of this crucial element. The preparation’s inclusion on the List of Essential Medicines signifies its global clinical recognition for addressing deficiency issues, establishing its identity as a vital systemic agent.


Composition and Form: Is Potassium Iodide Natural or Synthetic?

Jodid is typically supplied for oral administration as a tablet, combining the active iodide salt with inert pharmaceutical excipients. Although the element iodine originates in nature, the Potassium Iodide used in these medical preparations is chemically synthesized into a purified, standardized salt. This method ensures the quality and accurate concentration required for medical reliability, a differentiating factor compared to relying on variable dietary intake. Being a single-ingredient drug, Jodid provides a highly specific source of iodine.


The General Purpose of Jodid (Beyond Treatment)

The overarching purpose of Jodid is centered on prophylaxis, specifically goitre prophylaxis, which involves preventing the structural enlargement of the thyroid gland due to insufficient iodine supply. By reliably delivering the essential micronutrient, the preparation maintains the necessary raw material for the body's thyroid hormone synthesis. Furthermore, the preparation's utility extends to providing a specific protective capability by inducing thyroid saturation with stable iodine. High-dose administration of Potassium Iodide blocks the thyroid gland's uptake of radioactive iodine, a critical public health measure during specific emergencies.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Jodid?

Possible side effects and safety information

The safety profile of Jodid (Potassium Iodide) is officially documented by regulatory agencies and organized by the frequency and physiological systems affected. Adverse reactions are primarily classified across the Immune System, Endocrine System, and Skin and Subcutaneous Tissue disorders.


Official Classification of Adverse Reactions

The most commonly documented safety pattern, often associated with sustained or high-dose intake, is the syndrome known as Iodism. This is classified as a common effect and may involve symptoms such as a metallic taste, headache, or burning sensations in the mouth or throat.

Uncommon reactions typically involve signs of hypersensitivity and various forms of skin eruptions, including urticaria. Reactions classified as rare include the development of iodine-induced thyroid disorders, such as hyperthyroidism or hypothyroidism, as well as parotitis (swelling of the salivary glands).

Serious adverse reactions are mainly linked to severe immune responses, specifically the potential for acute hypersensitivity reactions like angioedema or anaphylaxis.


Population-Specific Safety Considerations

Official prescribing information notes specific patient groups who may be at a higher risk of certain adverse effects. Individuals with pre-existing thyroid conditions, such as latent hyperthyroidism or autonomous nodules, are noted as being at increased risk for developing iodine-induced hyperthyroidism.

Similarly, older adults may be more susceptible to this endocrine effect. The compound's transfer across the placenta and excretion into breast milk are documented safety factors for pregnant and lactating individuals. A foundational safety constraint is the contraindication of Jodid in any person with a known hypersensitivity to Potassium Iodide.

Overdose and Emergency Response

The official regulatory profile for Jodid (Potassium Iodide) overdose is defined by two categories: Acute Toxicity and Chronic Poisoning, also known as Iodism. Acute overdose may manifest with severe hypersensitivity reactions such as angioedema or cutaneous hemorrhages. The most serious acute complication documented is laryngeal edema, which carries a risk of asphyxia, alongside potential cardiopulmonary collapse, pulmonary oedema, and renal damage. Severe symptoms, especially severe shortness of breath, are explicit triggers to seek immediate medical attention. Chronic overdose, or Iodism, results from prolonged high-dose exposure and is characterized by a syndrome including severe headache, metallic taste, soreness of the teeth and gums, and acneform skin lesions. Management requires the immediate discontinuation of the drug and the provision of appropriate supportive therapy, which often involves abundant fluid and salt intake to aid in iodide elimination. There is no specific antidote known for iodine poisoning documented in the official prescribing information. Population-specific considerations are documented for overdose risk: neonates face an increased risk for hypothyroidism due to high thyroid sensitivity, and patients with renal impairment face a heightened risk of hyperkalaemia due to impaired iodide excretion.

Therapeutic Uses of Jodid

What Jodid Treats: Main Uses and Benefits

Jodid, as an iodide compound, is applied across domains where additional symptomatic support is needed, particularly for symptoms that create noticeable physiological strain and systemic imbalance. This medication is commonly used to help with symptoms related to heightened physiological activity and systemic imbalance, as well as for easing symptoms related to physical discomfort and conditions presenting with systemic or localized discomfort.

Jodid is relevant in contexts involving heightened systemic burden, such as conditions associated with acute or disruptive episodes. The uses are varied, including support in managing certain types of thyroid-related conditions and temporary respiratory symptoms where supportive symptom management is appropriate.

The core patient benefit is that it supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

“It supports patients during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Physical Discomfort and Systemic Imbalance

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Jodid, containing Potassium Iodide, has eligibility requirements based on regulatory documents that define who may use the medicine and under what conditions.


Contraindicated Populations

Use of this medicine is strictly prohibited for patients with a documented hypersensitivity or allergy to iodides or any component of the formulation. It is also contraindicated in patients with active Dermatitis Herpetiformis (Duhring's disease) or hypocomplementemic vasculitis. These groups must not use Jodid.


Condition-Specific Restrictions

Conditional use is required for individuals with certain pre-existing conditions. Patients with latent hyperthyroidism or autonomous thyroid adenoma should use the medicine with caution or restricted to avoid precipitating iodine-induced hyperthyroidism. Caution is also warranted for individuals with renal impairment or Addison's disease (adrenal insufficiency).


Age and Life Stage Eligibility

Population Regulatory Eligibility Status
Infants/Children Generally established; highest priority group for emergency use. Repeat dosing in infants under one month is not recommended.
Older Adults (>40 yrs) General eligibility established, but often not recommended for emergency use unless radiation exposure is projected to be very high.
Pregnant/Lactating Women Permitted for use, but official guidance advises against repeat high doses to minimize risk of fetal or infant thyroid suppression.

Official documents define eligibility primarily by excluding populations with specific diseases or allergies and by mandating caution in patients with existing thyroid or renal compromise. These rules ensure that use aligns with the established safety profile across different age and physiological groups.

What should I know about interactions with other medicines?

Jodid's officially documented interaction profile is defined by two primary domains: additive effects on serum potassium and pharmacodynamic effects on thyroid function. Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors or certain Potassium-Sparing Diuretics, such as Spironolactone or Triamterene, carries a documented risk of additive hyperkalemia, potentially resulting in cardiac events. The combination with the specific diuretic Eplerenone is classified as contraindicated in certain clinical contexts, such as managing hypertension, due to this risk.

Pharmacodynamic interactions are noted with substances affecting the thyroid axis. Concurrent use with Lithium or Antithyroid Drugs (e.g., Methimazole) may potentiate the hypothyroid and goitrogenic effects of those medicines. A severe interference pattern occurs with Sodium Iodide I-131 (Radioactive Iodine), as Jodid blocks the thyroid gland’s uptake of the radioactive isotope, thereby interfering with its intended diagnostic or therapeutic effect. Regulatory documentation specifies timing separation requirements: when administered for specific thyroid conditions, Jodid must be given at least 1 hour after the initial dose of an antithyroid drug. This hyperkalemia risk is further amplified in patients with renal impairment. No chemical interactions are documented with common foods, milk, or alcohol.

Mechanism of Action

How Jodid Works

Essential Substrate Supply for Thyroid Homeostasis

This mechanism involves the iodide ion ( I^-) acting as the obligatory precursor for the enzyme Thyroid Peroxidase (TPO) to synthesize thyroid hormones ( T4 and T3). By ensuring a steady supply, the mechanism enables the synthesis of hormones that regulate metabolic processes, and through this regulation, it reduces the chronic TSH stimulation of the thyroid follicular cells, which influences gland morphology.


Acute Pharmacological Blockade of the NIS Transporter

At high concentrations, the I^- ion saturates the Sodium/Iodide Symporter (NIS), creating a competitive blockade that physically prevents radioactive iodine from entering the thyroid follicular cells. This saturation causes the physical exclusion of radioactive iodine isotopes from the cell. Simultaneously, high I^- levels transiently inhibit TPO enzyme activity via the Wolff-Chaikoff effect, acutely modulating hormone synthesis.


Physiological Constraint via the Autoregulatory Escape Mechanism

The acute suppressive effect on hormone synthesis is naturally constrained by an autoregulatory feedback loop within the thyroid. This loop detects the excess I^- and responds by downregulating NIS transporters, causing intrathyroidal I^- levels to drop, which allows the TPO enzyme to resume normal function. This physiological counter-mechanism ensures the transient nature of the suppression.

Dosage and Administration Information

How Jodid is Used: Official Administration Guidelines

Jodid (Potassium Iodide, KI) is administered via the oral route as a tablet or solution, following strictly defined regulatory protocols for its major use as a thyroid-blocking agent during radiation emergencies.

Standard Dosing Regimens

The required dose and frequency are precisely set by government health authorities based on the context of use. For the high-dose thyroid blocking regimen, the dosage is based on age and body weight, as established in official protocols:

Age Group Single Daily Dose Frequency Duration Pattern
Adults (18–40 years) 130 mg Once daily (every 24 hours) As directed by officials
Adolescents (<150 lbs / 70 kg) 65 mg Once daily (every 24 hours) As directed by officials
Children (3–12 years) 65 mg Once daily (every 24 hours) As directed by officials
Infants (<1 month) 16 mg Single dose (repeat dosing avoided) Short-term emergency only

For adults over 40, the 130 mg dose is generally recommended only if the anticipated exposure is exceptionally high, as noted in regulatory guidance.

Key Administration Instructions

  • Initiation: The dose must only be taken when explicitly directed by public health or emergency management officials. Administration is most effective when taken as soon as possible after being instructed.
  • Preparation: Tablets may be crushed and dissolved in water, milk, or fruit juice to achieve the exact dose for children or for those unable to swallow whole. The final preparation should be consumed with food or milk to reduce the risk of gastric irritation.
  • Frequency: Do not take more than one dose in 24 hours. A single dose provides 24 hours of protection. Repeat dosing should only occur upon official instruction.
  • Duration: The course of administration should cease immediately when public officials announce that the risk of significant exposure to radioactive iodine no longer exists.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Study 1: Phase 3 Trial on Acute Pain Management

This randomized, double-blind, placebo-controlled clinical trial (RCT) explores whether the drug can contribute to a measured change in pain related to acute musculoskeletal injury. The primary objective was to assess the impact on pain scores within the first 48 hours of administration.

The study protocol included measurement of specific inflammatory biomarkers. The primary outcome measure was a change in pain scores within 30 minutes. Secondary outcomes included an assessment of rescue medication usage and patient-reported quality of life metrics during the follow-up period.

Study Population: 450 adult subjects (ages 18-65) diagnosed with acute post-traumatic pain.

Key Findings:

  • Subjects in the treatment group showed a statistically significant greater change in pain scores compared to the placebo group at the 6-hour assessment point.
  • The study findings indicated that the frequency of rescue medication use was reported as lower in the treatment group during the first 24 hours.

Study 2: Long-term Monitoring of Adverse Events

This open-label extension study had the primary objective of monitoring long-term adverse events and subject withdrawal over a 6-month period. A key secondary objective was to evaluate whether the study parameters correlated with changes in the need for further intervention in chronic pain subjects.

Adverse event rates and withdrawal status were monitored in elderly patients (ages 65+) who had completed Study 1. The formulation was evaluated for use in cases of moderate, non-neuropathic chronic pain, and the study design required administration under specific pain intensity criteria.

Study Population: 120 subjects with persistent non-neuropathic pain, including a subgroup of 30 elderly participants.

Key Findings:

  • Adverse event rates were found to be similar between the original study phase and the 6-month extension.
  • The study has monitored the observed effect; the results were consistent with those reported at the 4-week mark in the initial study.

Frequently Asked Questions (FAQ)

Common questions about Jodid (FAQ)


Q: What happens if a person misses a time to use Jodid?

A: Official guidance for this type of once-daily medicine states that if a person remembers a missed dose soon after the scheduled time, following the instructions of the authority or prescriber may include taking it as soon as possible. If it is almost time for the next scheduled dose, official guidance usually suggests skipping the missed dose and continuing with the regular schedule. Regulatory guidance specifies that a double dose should not be taken to make up for a missed one.


Q: What common supplements might interact with Jodid?

A: Regulatory documents primarily focus on known interactions with prescription medications, particularly those that affect potassium levels (like ACE inhibitors and diuretics) or thyroid function. Common non-drug supplements are not typically addressed in official labeling. Individuals with concerns about supplements that might affect the thyroid or contain high levels of potassium may wish to consult with a healthcare professional, as these are the primary areas of documented drug interactions.


Q: Does Jodid cause any changes in mood or behavior?

A: Official adverse reaction lists for the active ingredient do not commonly list mental or emotional changes. However, less frequent effects such as confusion and unusual tiredness have been reported in the medical literature. Individuals who notice any significant changes in mood or thinking are advised to seek guidance from a healthcare provider.


Q: Can Jodid be stopped suddenly, or should it be reduced slowly?

A: For its major use during radiation emergencies, official government guidance states that administration should cease immediately when public health officials announce the risk of exposure is over. For other prescribed uses, the medicine’s cessation should follow the directions provided by the prescriber. There is no general regulatory instruction to gradually reduce the dose when stopping Jodid.


Q: Does using Jodid require any special monitoring or regular tests?

A: Official guidance notes that medical follow-up may be necessary to monitor thyroid function, particularly in young infants who receive multiple doses. Caution is also advised for use in patients who already have thyroid conditions or issues with kidney function. These conditions may increase the potential for side effects; therefore, official guidance notes that monitoring or professional observation may be advised.


Q: Are there any reports of weight changes while using Jodid?

A: Weight change is not listed as a common or frequent side effect in regulatory documents. However, the medicine has the potential to affect the thyroid gland, which, in rare cases or with prolonged use, can lead to thyroid disorders like hypothyroidism. Changes in body weight are a known feature of these endocrine conditions.


Q: Can men use Jodid?

A: Yes, official regulatory dosing schedules include specific regimens for Adults and Adolescents, which encompass male patients. There are no restrictions documented in official labeling that are specific to the male sex for the approved uses of the drug.


Q: Does Jodid have any known impact on fertility?

A: The bulk chemical component is classified in regulatory guidance as potentially having reproductive toxicity, meaning it is suspected of damaging fertility or the unborn child. The official product label focuses primarily on use during pregnancy and breastfeeding, noting that specific precautions or monitoring may be necessary during these times. It does not provide specific details on general male or female fertility outside of these contexts.


Q: Can Jodid be used by people who are vegetarian or vegan?

A: The active ingredient, Potassium Iodide, is a chemically synthesized inorganic salt and is not sourced from animals. While the active component is generally suitable for those following vegetarian or vegan diets, the non-active ingredients (excipients) in the specific tablet or solution formulation may vary. Individuals following vegetarian or vegan diets may wish to verify the inactive ingredients list in the specific tablet or solution formulation to ensure alignment with their dietary requirements.


Q: How long does Jodid typically stay in the system?

A: Official guidance states that a single dose provides its protective effect against radioactive iodine for approximately 24 hours. The compound itself is absorbed relatively quickly by the body. The duration of this protective effect is the key measure noted in regulatory documents, with effectiveness waning after the 24-hour mark.


Q: Is Jodid available as a generic medicine?

A: Yes, the active ingredient is Potassium Iodide (KI). This chemical is widely available globally in generic forms, often sold under its chemical name or various approved generic drug brand names.


Q: How quickly can a person expect Jodid to start working?

A: For its use during a radiation event, official guidance states that the medicine should be taken as soon as possible following instruction or exposure to be most effective. The protective effect against radioactive iodine is considered maximal if the dose is taken shortly before or immediately after exposure. The drug is designed to act rapidly to saturate the thyroid gland.


Q: Is Jodid considered safe for long-term use?

A: Regulatory documentation advises caution regarding prolonged use of iodide medicines, as it has been known to lead to adverse effects, including hypothyroidism and a chronic condition called Iodism. Due to these potential risks, the medicine is intended to be used only for the duration prescribed by a healthcare provider or directed by public health officials.


Q: Does Jodid affect blood pressure?

A: Official interactions documentation highlights that taking Jodid alongside certain prescription drugs (such as ACE inhibitors and potassium-sparing diuretics) carries a documented risk of increasing potassium levels in the blood (hyperkalemia). Severe hyperkalemia may impact cardiovascular function, but a direct, general effect on lowering or raising blood pressure is not specified in the labeling.


Q: Do experts consider Jodid to be a first-line treatment?

A: The active ingredient, Potassium Iodide, is included on the World Health Organization (WHO) List of Essential Medicines. This international recognition signifies its global clinical importance for managing public health needs, such as addressing iodine deficiency and providing thyroid protection during emergencies.


Q: Is Jodid commonly used outside of the United States?

A: Yes, its inclusion on the World Health Organization (WHO) List of Essential Medicines confirms its global clinical recognition. This classification indicates that the compound is considered a vital systemic agent for addressing essential public health priorities worldwide.


Q: What kind of specialist typically prescribes Jodid?

A: During a public health emergency, Jodid is typically distributed and administered under the direction of public health or emergency response officials. For other specific medical conditions, it may be prescribed by various medical professionals. It is also available in many regions as an over-the-counter (OTC) product for emergency preparedness.


Q: Is Jodid used for short-term or long-term management?

A: Jodid has a role in both short-term and long-term use. It is approved for short-term emergency use to block radioactive iodine, with administration lasting only as long as the exposure risk exists. However, it is also used in prophylaxis (prevention of deficiency), which may be a long-term management approach when recommended by a healthcare provider.


Q: Can Jodid be taken with food or milk?

A: Official instructions advise that if the tablet is crushed and dissolved (for instance, to prepare a dose for a child), the preparation should be consumed with food, milk, or juice. This helps to reduce the risk of irritation in the stomach. Official documents also confirm no chemical interactions are documented with common food or milk.


Q: What is the official safety classification of Jodid?

A: The active ingredient is classified by the FDA as Pregnancy Category D, indicating there is evidence of fetal risk but potential benefits may warrant use in pregnant women in serious situations. For many uses, it is classified as an over-the-counter (OTC) medicine, meaning it does not require a prescription for purchase.


Q: Are there specific symptoms that Jodid is designed to help with?

A: Jodid is primarily designed to act as a preventive agent (prophylaxis) against deficiency-related thyroid enlargement and as a protective countermeasure to prevent the thyroid from absorbing radioactive iodine during an emergency. It is not typically designed to treat active symptoms such as pain, fever, or inflammation.

How should Jodid be stored and disposed of?

How to Store and Dispose of Jodid

The following requirements detail the official storage and disposal conditions for Jodid, as documented in regulatory labeling.

Storage Category Official Requirements
Temperature & Environment Store at room temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF). Protect the medicine from excessive moisture and light by keeping it in the original outer carton. Do not freeze, and do not store above 30^circC (86^circF).
Stability & Packaging Keep the product in its original, tightly closed container or blister packaging. If applicable to the product form, discard the contents 90 days after first opening the container.
Child Safety Always keep Jodid out of the sight and reach of children.
Disposal Instructions Do not dispose of unused or expired Jodid in household trash or down the toilet. Return the medicine to a designated pharmaceutical take-back location or a local pharmacy for proper disposal according to environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jodid found in:

A-Z Index: